Bain Capital Life Sciences Investors, LLC bought KLRA

April 20, 2026 · Form 4 insider transaction

Bain Capital Life Sciences Investors, LLC bought 16,875,000 shares of Kailera Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Acquired (buy-side)
Shares
16,875,000
Price
N/A
Total value
N/A
Role10% owner
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateApril 20, 2026
Filing dateApril 20, 2026
Shares owned after16,875,000
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.; Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").; Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

View the original Form 4 on SEC EDGAR
Bain Capital Life Sciences Investors, LLC bought KLRA: April 20, 2026 | Insider Trading Screener